
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
BioPharm International is look for case study submission of filtration practices.
BioPharm International magazine is seeking case studies about successful filtration practices. Please submit a short (300-word maximum) abstract describing your study to Laura Bush at







